Specific BACE1 inhibitors have also been developed, and some of the inhibitors have been evaluated in clinical trials of Alzheimer’s disease [16,17,18,19,20]. The gene discussed is BACE1; the disease is early-onset autosomal dominant Alzheimer disease.